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Efflux pumps are integral plasma membrane protein systems that 
recognize and bind noxious compounds present in the cytoplasm 
(toxic products produced by metabolism; compounds that have 
penetrated the cell), or periplasm of the bacterial cell and extrude it into 
the environment in which the bacterium resides [1]. The efflux pump 
machinery gives the cell additional protection to the one provided 
by the constituents of its cell wall (example: lipopolysaccharides), 
and provides an initial protection to noxious agents present in its 
natural environment that have penetrated into the cell (example: bile 
salts in the colon) [1]. The efflux pump machinery is divided into 
five superfamily classes; the major facilitator (MF), the ATP-binding 
cassette (ABC), the resistance-nodulation-division (RND), the small 
multi-drug resistance (SMR) and the multi-drug and toxic compound 
extrusion (MATE). With respect to Gram-negative bacteria, although 
they all play important roles in the protection of the bacterium from 
noxious agents present in the environment, the main efflux pump of 
the Gram negative bacterium is a member of the RND superfamily, and 
because multi-drug resistance of clinical isolates have been associated 
with the over-expression of this pump, it has received a great deal of 
attention [2]. 
The first in vitro response of bacteria to a given noxious agent, 
such as an antibiotic, is to over-express its main efflux pump [2]. If the 
bacterium is serially exposed in vitro to increasing concentrations of that 
compound, it responds by increasing the effective number of its main 
efflux pump, as well as others that provide redundant protection [2]. 
However, if that “adapted” bacterium is now maintained at a constant 
level of a noxious agent, the level of efflux pump activity increases up to 
a maximum, followed by a gradual return of efflux pump activity to its 
basal level. Concomitant to this process, an accumulation of mutations 
of essential proteins located in the plasma membrane (example 
penicillin binding proteins), mutations 30 S component of the ribosome 
and gyrase take place [3]. These events suggest that when the organism 
is faced with an environment that contains a constant toxic level of a 
compound, and the cost for maintaining an energy consuming system, 
such as that needed for the energy dependent efflux pump, is too 
great a price to pay. Therefore, in order to survive in this unchanging 
environment, other mechanisms are activated. For example, activation 
of a mutator master gene is thought to be an important step at this 
level, which results in the mutation of genes that code for essential 
proteins, reversing the over-expression of efflux-pumps, but still 
conferring the bacterial resistant to the environmental pressure via 
other mechanism(s), yet to be understood [4,5]. This sequence of 
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events can be an explanation for what takes place when a patient is 
treated with an ineffective constant dose of antibiotic(s). During such 
therapy, the level of resistance increases many fold higher than that of 
the initial infecting strain. Hence, clinical isolates from treated patients 
often show much higher levels of antibiotic resistance than that of 
their wild type counterpart (sometimes it can even present a 1000 fold 
increase) [6]. Moreover, at this stage, resistance is usually related with 
the presence of mutations, which reduces the survival of the resistant 
bacteria, once it is transferred to a noxious agent-free environment 
that contains the competing wild type counterpart [3,4]. However, 
depending upon when during therapy a clinical strain is isolated, its 
resistance to two or more antibiotic classes (multi-drug resistance 
(MDR)), may be due entirely to over-expressed efflux pumps; to a 
mixture of over-expressed efflux pumps and increasing accumulation of 
mutations; and only to mutations [3,4]. The degree of resistance due to 
any of the aforementioned possibilities can readily be determined with 
methods that employ compounds known for their modulation of efflux 
pump activity, such as phenothiazines [7] or phenyl-arginine-beta-
naphthylamide (PAβN), the latter which competes with the antibiotic 
as substrate of the efflux pump [8]. If in presence of such compounds, 
the MDR bacterium is rendered fully susceptible to the antibiotic(s) to 
which it was initially resistant, resistance is most likely due to its over-
expressed efflux pump systems. Contributions made by accumulated 
mutations render the organism less and less affected by the EPI. This 
type of information is of great value to clinicians faced with long-term 
therapy of a bacterial infection that progresses to an MDR phenotype. 
It should be understood that although the Gram-negative bacterium 
has essentially one main efflux pump, such as the AcrAB (Escherichia 
coli) or the MexAB (Pseudomonas aeruginosa), the deletion of the main 
efflux pump results in the over-expression of one or more other RND 
efflux pumps, such as is the case for deletion of the AcrAB, followed by 
the over-expression of the AcrEF pump [2]. Redundancy of as many 
as nine RND efflux pumps [2], provides additional protection to the 
organism. 
Understanding the physical chemistry, physiology and regulation 
of efflux pumps of Gram-negative bacteria is, therefore, important for 
the development of drugs that may be used as adjuvants, in combination 
with antibiotics for therapy of an efflux pump dependent MDR Gram-
negative infection. The main efflux pumps of Gram-negatives are 
members of the resistance-nodulation-division (RND) superfamily.
The pumps belonging to the RND family form a tripartite complex 
together with the periplasmic proteins belonging to the membrane-
fusion-protein (MFP) family and the outer membrane channels. RND 
transporters consist of a transporter protein that recognises and binds 
the noxious agent in the cytoplasm or periplasm and transports it 
to the contiguous channel (TolC), ending at the surface of the outer 
membrane. The transporter is attached to the plasma membrane by 
two or three fusion proteins, which are believed to assist the extrusion 
of the substrate by peristaltic actions [9]. Although the actual structure 
of RND efflux pumps in the cell envelop is not completely understood, 
the structure of the transporter, TolC and fusion proteins are well 
established for major Gram-negative bacteria [10]. 
RND efflux pumps obtain their energy for activity from the proton 
motive force (PMF). The PMF results from metabolic activity of the 
cell. However, whereas at pH above 6.5, the efflux pump is totally 
dependent upon metabolic activity controlled by the ATP synthase, at 
lower pH efflux activity is independent of metabolism [11]. Because 
the dissociation constant of the bound substrate from the transporter 
is pH dependent (at pH of 7 dissociation is very slow compromising 
the activity of the pump), we have from many of our studies concluded 
that the PMF energy dependent efflux pump most likely needs the 
passage of hydronium ions through its internal cavity, for the release 
of the substrate that is in turn ejected into the TolC channel via the 
peristaltic action of the fusion proteins [11]. Because at low pH, the 
concentration of hydronium ions at the surface of the cell results in 
a pH difference of 2 or 3 pH units, as opposed to that of the milieu, 
the surface concentration of hydronium ions provides the force for the 
mobility of hydronium ions through porins leading to the acidification 
of the periplasm, and thereby, providing the low pH needed by 
the transporter for the release of the substrate. At high pH, these 
hydronium ions come from hydrolysis of ATP by ATP synthase, and 
are therefore, passed into the transporter, thereby reducing its internal 
pH, so that the release of the substrates can take place [11,12]. EPIs, 
such as the phenothiazines chlorpromazine or thioridazine, exert their 
inhibition at pH above 6, and are believed to affect hydrolysis of ATP, 
hence, denying the efflux pump transporter hydronium ions needed 
for release of the bound substrate [11,12]. The search for EPIs that are 
clinically useful continues, although with respect to thioridazine, this 
old neuroleptic has been shown to inhibit efflux pumps of pathogenic 
mycobacteria [13], and has been successfully used to treat extensively 
drug resistant tuberculosis infections [14]. 
Moreover, the regulation of the main efflux pump of Escherichia 
coli may take place via distinct pathways. The induced synthesis of the 
transporter component of the AcrAB efflux pump, when the organism 
is exposed in vitro to a noxious agent, involves the activation of the 
stress gene soxS, followed by the activation of the local regulator marA, 
and then by the activation of the transporter gene acrB [8]. On other 
hand, in case of Salmonellaspp. two component resistance mechanisms, 
such as the PmrA/PmrB system, directly activate the master efflux 
pump regulator ram A g ene [15]. The activation of the PmrA/PmrB 
system takes place readily when Salmonellaspp. is phagocytosed due 
to the acidic nature of the phagolysosome [15], as follows: PmrB is a 
sensor that self-phosphorylates, and then transfers the phosphate to 
PmrA. PmrA activates a nine gene operon, which eventually codes for 
Lipid A that is introduced into the nascent lipopolysaccharide layer of 
the outer membrane. The increased presence of Lipid A renders the 
phagocytosed bacterium practically immune to everything, including 
the hydrolases of the phagolysososome [15]. It is for this reason that 
when Salmonella spp. that invades the peritoneum from a resected 
colon produces high mortality, even though the neutrophil has in 
essence done its job. 
The role of efflux pumps in the therapy of MDR bacterial infections 
is still evolving, and the need for adjuvants that are safe and effective 
for rendering the MDR bacterium susceptible to antibiotics is obvious. 
Moreover, because the EPI may render MDR bacteria susceptible to old 
antibiotics that have fallen out of use, their economic potential benefit 
is huge. Although some EPIs are in clinical trials, none have yet to reach 
the marketplace, mainly due to their common toxicity against healthy 
mammalian cells, affecting intrinsic mammalian efflux pumps, as for 
example those of the blood brain barrier. Lastly, it should be noted 
that compounds that inhibit the efflux pump of bacteria also have 
the capacity to promote the removal of plasmids that carry antibiotic 
resistant genes [16,17]. This alone has huge implications for the animal 
husbandry industry, and is worth considering. 
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